A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

NCT07285902 · Active, not recruiting

Last updated 2026-05-28

This clinical trial compares the effects and safety of HRS9531 injection to semaglutide injection in adults with obesity over a 52-week period.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 572 people

Who can join Ages 18+ · all sexes

Timeline Started 2025-12 · est. completion 2027-03

Where 2 sites · China

What this study is testing ClinicalTrials.gov NCT07285902 ↗

Description as written by the study sponsor.

This study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity

Treatments tested

HRS9531 injection Drug

HRS9531 injection
Semaglutide Injection Drug

Semaglutide Injection

Main thing measured	Percentage change from baseline in body weight after 52 weeks of treatment
Sponsor	Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions studied	Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07285902 ↗